🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

242 results for “ANI” Clear

  1. ONDANSETRON , APREPITANT , PALONOSETRON, COMBINATIONS, PALONOSETRON , Lagipra, GRANISETRON , DEXAMETHASONE , 0.9% sodium chloride

    Eli Lilly Co.

    Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms

    phase 2 small molecule active

    1 trial

  2. OXALIPLATIN, AFLIBERCEPT, PANITUMUMAB, BEVACIZUMAB, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, IRINOTECAN, FLUOROURACIL, CETUXIMAB, AVELUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    phase 2 small molecule active

    1 trial

  3. OXALIPLATIN, PANITUMUMAB, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, BEVACIZUMAB, NIVOLUMAB, TRASTUZUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment

    phase 2 small molecule active

    1 trial

  4. Opaganib

    RedHill Biopharma

    Coronavirus Infections

    phase 2 small molecule completed

    1 trial

  5. Opaganib

    Apogee Therapeutics

    Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  6. PD-L1, PD-L2 peptides with Montanide ISA51

    IO Biotech

    Chronic Lymphocytic Leukemia

    phase 2 other completed

    1 trial

  7. Panitumumab

    United Therapeutics Europe Ltd

    Metastatic Colon Adenocarcinoma

    phase 2 mab active

    1 trial

  8. Panitumumab

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Head and Neck Squamous Cancer

    phase 2 small molecule completed

    1 trial

  9. Panitumumab

    Takeda Pharmaceuticals International AG

    Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule completed

    1 trial

  10. Panitumumab + TAS-102

    Takeda Pharmaceuticals International AG

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  11. Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Paclitaxel AqVida 6 mg/ml concentrate for solution for infusion, REGN7075, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., LIBTAYO 350 mg concentrate for solution for infusion., Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Pharma Mar S.A.

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Peptide A49 associated to melanin, Peptide A52 associated to melanin, Litenimod solution

    Pari Pharma GmbH

    glioblastoma

    phase 2 small molecule active

    1 trial

  13. PvCS/Montanide ISA-51 VG Vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    Plasmodium Vivax Malaria

    phase 2 mab active

    1 trial

  14. RO7234292, RO7234292 Placebo

    Roche Registration Limited

    Prodromal and Early Manifest Huntington’s Disease

    phase 2 small molecule active

    1 trial

  15. Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection

    Sunshine Biopharma

    Psoriasis

    phase 2 small molecule active

    1 trial

  16. Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg

    Sunshine Biopharma

    Gout Arthritis

    phase 2 small molecule active

    1 trial

  17. Recombinant anti-PD-1 humanized monoclonal antibody injection

    Sunshine Biopharma

    Sarcoma, Soft Tissue

    phase 2 small molecule active

    1 trial

  18. Scaling and root planing, and Septilin for 7 days

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Periodontitis

    phase 2 small molecule completed

    1 trial

  19. Sodium Cridanimod

    Xenetic Biosciences

    Endometrial Cancer

    phase 2 small molecule terminated

    1 trial

  20. Teicoplanina Sandoz 200 mg polvere e solvente per soluzione iniettabile o infusione o soluzione orale

    Verona Pharma Ireland Limited

    cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection

    phase 2 small molecule active

    1 trial

  21. Tizanidine (sublingual or oral)

    Teva Pharma GmbH

    Muscle Spasticity

    phase 2 small molecule completed

    1 trial

  22. Tovorafenib, Tovorafenib

    AXIM BIOTECHNOLOGIES, INC.

    craniopharyngioma

    phase 2 small molecule active

    1 trial

  23. Valbenazine Oral Capsule

    NEUROCRINE BIOSCIENCES INC

    Trichotillomania (Hair-Pulling Disorder)

    phase 2 small molecule active

    1 trial

  24. ZW25 (Zanidatamab)

    Beone Medicines Ireland Limited

    HER2-amplified Biliary Tract Cancers

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources